GeoVax DNA/MVA HIV vaccine, preclinical and clinical studies

In Therapeutic Vaccines by Freya SmaleLeave a Comment

download, HIV vaccine

GeoVax DNA/MVA HIV vaccine, preclinical and clinical studies

· Comparison of preclinical and clinical responses to those in the protective (31%) Rv144 trial

· Elicitation of protective antibody by display of native Env (gp160) on virus-like particles

· Co-expression of GM-CSF to enhance mucosal and systemic antibody responses

Dr Harriet Robinson, Chief Scientific Officer, GeoVax

This presentation covers the following:

•Findings in Phase 1 and 2a clinical trials

•Rationale for advancing 2nd generation vaccine

•2nd generation HIV vaccine

•Clinical status of 2nd generation vaccine

Download the full presentation here >

To learn more about this and the other topics discussed at the World Vaccine Congress Lyon 2012, please click here >

For more updates on the vaccines industry, follow us on Twitter: @vaccinenation or join our LinkedIn group: Vaccine Nation

Leave a Comment

Current ye@r *